ArticleNanomedicine (London, England)2011
Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells.
Article in Nanomedicine (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Nanomedicine to Overcome Current Parkinson's Treatment Liabilities: A Systematic Review.Neurotoxicity research · 2016Pooled it
- Exosomes in brain diseases: Mechanisms, advances, and perspectives.Bioactive materials · 2027Review
- Engineering exosomes for targeted neurodegenerative therapy: innovations in biogenesis, drug loading, and clinical translation.Theranostics · 2026Review
- MiR-184 Mediated the Expression of ZNF865 in Exosome to Promote Procession in the PD Model.Molecular neurobiology · 2024Article
- Immune cells: potential carriers or agents for drug delivery to the central nervous system.Military Medical Research · 2024Review
- Exosome-Based Drug Delivery: Translation from Bench to Clinic.Pharmaceutics · 2023Review
- Nanomedicine in the Face of Parkinson's Disease: From Drug Delivery Systems to Nanozymes.Cells · 2022Review
- Role of exosomes in the pathogenesis of inflammation in Parkinson's disease.Neural regeneration research · 2022Review
- Extracellular Vesicles Mediate the Intercellular Exchange of Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Biodistribution of Biomimetic Drug Carriers, Mononuclear Cells, and Extracellular Vesicles, in Nonhuman Primates.Advanced biology · 2022Article
- Role of macrophage in nanomedicine-based disease treatment.Drug delivery · 2021Review
- Formulation and Efficacy of Catalase-Loaded Nanoparticles for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy.Pharmaceutics · 2021Article
- Delivery of Cinnamic Aldehyde Antioxidant Response Activating nanoParticles (ARAPas) for Vascular Applications.Antioxidants (Basel, Switzerland) · 2021Article
- T Cell-Mediated Transport of Polymer Nanoparticles across the Blood-Brain Barrier.Advanced healthcare materials · 2021Article
- Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment.Frontiers in pharmacology · 2021Review
- Nose-to-Brain Delivery of Antioxidants as a Potential Tool for the Therapy of Neurological Diseases.Pharmaceutics · 2020Review
- Genetically modified macrophages accomplish targeted gene delivery to the inflamed brain in transgenic Parkin Q311X(A) mice: importance of administration routes.Scientific reports · 2020Article
- GDNF-expressing macrophages restore motor functions at a severe late-stage, and produce long-term neuroprotective effects at an early-stage of Parkinson's disease in transgenic Parkin Q311X(A) mice.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Accessing neuroinflammation sites: Monocyte/neutrophil-mediated drug delivery for cerebral ischemia.Science advances · 2019Article
- TPP1 Delivery to Lysosomes with Extracellular Vesicles and their Enhanced Brain Distribution in the Animal Model of Batten Disease.Advanced healthcare materials · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundOur laboratories forged the concept of macrophage delivery of protein antioxidants to attenuate neuroinflammation and nigrostriatal neurodegeneration in Parkinson's disease. Notably, the delivery of the redox enzyme, catalase, incorporated into a polyion complex micelle ('nanozyme') by bone marrow-derived macrophages protected nigrostriatum against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication. Nonetheless, how macrophage delivery of nanozyme increases the efficacy of catalase remains unknown.
methodsIn this study, we examined the transfer of nanozyme from macrophages to brain microvessel endothelial cells, neurons and astrocytes.
resultsFacilitated transport of the nanozyme from macrophages to endothelial, neuronal and glial target cells occurred through endocytosis-independent mechanisms that involved fusion of cellular membranes, macrophage bridging conduits and nanozyme lipid coatings. Nanozyme transfer was operative across an artificial blood-brain barrier and showed efficient reactive oxygen species decomposition.
conclusionThis is the first demonstration, to our knowledge, that drug-loaded macrophages discharge particles to contiguous target cells for therapeutic brain enzyme delivery. The data shown are of potential value for the treatment of neurodegenerative disorders and notably, Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.